Lumateperone (Caplyta)

What it treats

Lumateperone is FDA-approved for schizophrenia in adults and for depressive episodes of bipolar I and bipolar II disorder in adults, both as monotherapy and as add-on to lithium or valproate. It's often reached for when metabolic side effects have been a real problem with previous antipsychotics or when bipolar depression hasn't responded to first-line options.

How it works

Lumateperone acts on serotonin, dopamine, and glutamate systems together. It blocks serotonin 5-HT2A receptors and modulates dopamine D2 activity in a way that's different from most other antipsychotics. It also affects glutamate signaling indirectly, which may explain some of its antidepressant effect in bipolar depression.

Receptor mechanism (detail)

Lumateperone is a 5-HT2A antagonist with an unusual dopamine profile: it acts as a pre-synaptic partial agonist and post-synaptic antagonist at D2 receptors, which some pharmacologists call a "sweet spot" dopamine effect that gives clinical benefit with less movement side effect. It also modulates glutamate signaling through NMDA receptor phosphorylation. It has low histamine, muscarinic, and adrenergic activity, which explains the lighter side-effect profile.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual. Lumateperone is dosed at a fixed 42 mg once daily, without titration.

Safety monitoring

• Weight, BMI, fasting glucose or HbA1c, and lipids at baseline and annually. Metabolic effects tend to be lighter than most atypicals.
• Blood pressure at baseline and periodically.
• Involuntary-movement screen (AIMS) every six months.
• Movement side-effect check at each early visit.
• Prolactin if symptoms appear.

Metformin co-commencement: Aoife Carolan / Schizophrenia Bulletin guideline.

A clinical guideline led by Aoife Carolan strongly recommends co-commencing metformin alongside high-risk antipsychotics like olanzapine or clozapine. This proactive approach helps mitigate severe metabolic side effects, significantly reducing antipsychotic-induced weight gain and improving insulin resistance. The Schizophrenia Bulletin guideline states that when prescribing olanzapine or clozapine, metformin should be initiated immediately to prevent weight gain and cardiometabolic issues. Lumateperone has a metabolically favorable profile and isn't on the automatic co-commencement list, but metformin is still recommended if weight rises more than 3 percent of pre-medication weight or if other cardiometabolic risk factors are present.

Typical titration used in the guideline: 500 mg once daily, then 500 mg twice daily after one week, then 500 mg increments every two weeks as tolerated, up to 1000 mg twice daily by about week six. Contraindicated with eGFR below 30 mL/min/1.73 m². Renal function is checked annually and metformin is held during acute illness or dehydration.

Source: Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.

What to expect

Common side effects

• Sedation.
• Dry mouth.
• Nausea, especially early.
• Fatigue.
• Dizziness.
• Mild weight change (small increase or steady).

Serious side effects and warnings

Boxed warning. Lumateperone carries the FDA boxed warning that antipsychotics increase the risk of death in older adults with dementia-related psychosis. It also carries the class boxed warning for increased suicidal thoughts and behaviors in children, adolescents, and young adults being treated for depression.

• Neuroleptic malignant syndrome. Rare but serious.
• Tardive dyskinesia. Long-term antipsychotic use can produce involuntary movements. Risk appears lower than with most first-generation antipsychotics but is still real.
• Metabolic changes, typically mild.
• Falls in older adults.
• CYP3A4 interactions. Strong CYP3A4 inhibitors or inducers change lumateperone levels and should be avoided.

This isn't medical advice. Any concern about a serious side effect should be raised with a prescriber promptly.

Sexual side effects

Sexual side effects are uncommon with lumateperone. Its low prolactin effect helps. If sexual side effects appear, it's worth raising with the prescriber.

Weight, appetite, and sleep

Weight tends to hold steady or shift only modestly. That's a real advantage over drugs like olanzapine and quetiapine. Sedation often helps sleep, especially with evening dosing.

Starting and dosing basics

This section is general background, not a dosing instruction. Lumateperone comes as a 42 mg capsule taken once daily. It can be taken with or without food. There's no titration, the starting dose is the maintenance dose.

Missed doses and interactions

If you miss a dose, take it when you remember unless it's almost time for the next one, then skip and carry on. Don't double up.

Lumateperone is metabolized by CYP3A4. Strong CYP3A4 inhibitors (some antifungals, some antibiotics, some antivirals) raise lumateperone levels and should be avoided. Strong CYP3A4 inducers (carbamazepine, rifampin, St. John's wort) lower levels and reduce effect. The prescriber and pharmacist need a full list of medications and supplements. Alcohol worsens sedation.

Stopping and tapering

Don't stop lumateperone abruptly. A prescriber can step down the dose gradually or transition to another medication.

Pregnancy and breastfeeding

Untreated psychosis and untreated bipolar depression both carry real risks in pregnancy, and lumateperone's data in pregnancy remains limited. Anyone who's pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber. This isn't medical advice.

Cost and generic availability

Lumateperone is brand-only. Cash prices are high. Manufacturer patient assistance programs exist, and many insurance plans cover it with prior authorization.

Common questions

How is lumateperone different from other atypicals? Two things stand out. First, its dopamine mechanism is unusual, a partial agonist at pre-synaptic D2 and antagonist at post-synaptic D2, which appears to give antipsychotic effect with less movement side effect. Second, its metabolic profile is genuinely lighter than most atypicals, weight and glucose typically shift less.

Does it work for depression? Yes, it's FDA-approved for bipolar depression in both bipolar I and bipolar II, either alone or added to lithium or valproate. That dual indication (schizophrenia and bipolar depression) is unusual.

Why only one dose? Clinical trials showed 42 mg once daily as the effective dose. There's no proven benefit to higher doses and no need for titration. That simplicity is one of its practical advantages.

Does it cause much weight gain? Generally no. Trial data suggests weight change tends to be small, well under what's seen with olanzapine or quetiapine. Individual responses still vary, which is why baseline and annual labs matter.

Questions to ask your prescriber

• Are we choosing this specifically for its metabolic profile?
• What are we hoping this treats, and how will we know it's working?
• Should we plan for AIMS screening every six months?
• Are there drugs I take that interact with CYP3A4?
• If we decide to stop it later, how would we transition?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes, and current as of June 8, 2026.

• U.S. Food and Drug Administration. Lumateperone (Caplyta) prescribing information.
• MedlinePlus, U.S. National Library of Medicine. Lumateperone.
• National Institute of Mental Health. Mental health medications.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd edition.
• National Institute for Health and Care Excellence (NICE). CG178, Psychosis and schizophrenia in adults.
• Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.